Royal Bank of Canada
FDMT icon

Royal Bank of Canada’s 4D Molecular Therapeutics FDMT Stock Holding History

Royal Bank of Canada’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9K Sell
979
-1,276
-57% -$11.1K ﹤0.01% 6199
2025
Q4 		$17K Sell
2,255
-169,855
-99% -$1.72M ﹤0.01% 6136
2025
Q3 		$1.5M Sell
172,110
-618
-0.4% -$3.69K ﹤0.01% 3640
2025
Q2 		$640K Buy
172,728
+172,263
+37,046% +$606K ﹤0.01% 4272
2025
Q1 		$1K Sell
465
-2,035
-81% -$9.59K ﹤0.01% 6657
2024
Q4 		$14K Sell
2,500
-2,896
-54% -$22.7K ﹤0.01% 6248
2024
Q3 		$59K Buy
5,396
+709
+15% +$11.8K ﹤0.01% 5615
2024
Q2 		$98K Buy
4,687
+2,877
+159% +$72.2K ﹤0.01% 5276
2024
Q1 		$57K Sell
1,810
-11,427
-86% -$292K ﹤0.01% 5475
2023
Q4 		$268K Buy
13,237
+6,752
+104% +$88.8K ﹤0.01% 4846
2023
Q3 		$83K Buy
6,485
+3,262
+101% +$54.6K ﹤0.01% 5508
2023
Q2 		$59K Buy
3,223
+1,479
+85% +$27.2K ﹤0.01% 5692
2023
Q1 		$30K Sell
1,744
-1,727
-50% -$33.6K ﹤0.01% 5867
2022
Q4 		$78K Buy
3,471
+3,036
+698% +$46.9K ﹤0.01% 5626
2022
Q3 		$3K Buy
435
+226
+108% +$2.05K ﹤0.01% 6880
2022
Q2 		$1K Sell
209
-1,547
-88% -$15K ﹤0.01% 7114
2022
Q1 		$27K Sell
1,756
-3,626
-67% -$56.9K ﹤0.01% 6441
2021
Q4 		$118K Buy
5,382
+3,038
+130% +$74.5K ﹤0.01% 5806
2021
Q3 		$63K Buy
2,344
+1,669
+247% +$47.6K ﹤0.01% 6020
2021
Q2 		$16K Sell
675
-38
-5% -$1.16K ﹤0.01% 6673
2021
Q1 		$31K Buy
+713
New +$31.6K ﹤0.01% 6181

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Royal Bank of Canada's FDMT Position: Q1 2026 in Review

Royal Bank of Canada reduced its 4D Molecular Therapeutics (FDMT) stake by 57% in Q1 2026, selling an estimated $11.1K and leaving 979 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #6199.

Royal Bank of Canada first reported a position in FDMT in Q1 2021 and has held it in 21 quarters since. The position peaked at $1.5M in Q3 2025. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Royal Bank of Canada held 979 shares of 4D Molecular Therapeutics worth $9K as of Q1 2026.
  • Royal Bank of Canada sold 1,276 4D Molecular Therapeutics shares in Q1 2026, an estimated $11.1K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6199 holding.
  • Royal Bank of Canada first reported a position in 4D Molecular Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • Royal Bank of Canada's 4D Molecular Therapeutics position peaked at $1.5M in Q3 2025.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.